Creative Biolabs Upgrades Rodent Behavioral Profiling Platform

Enhanced platform aims to accelerate CNS drug discovery by improving predictive preclinical models.

Mar. 21, 2026 at 7:48am

Got story updates? Submit your updates here. ›

Creative Biolabs has expanded its in vivo pharmacology capabilities with an upgraded rodent behavioral profiling platform designed specifically for central nervous system (CNS) research. The enhanced platform offers highly standardized evaluations of both cognitive and motor functions to help reduce the translational gap in the development of therapeutics for neurodegenerative diseases.

Why it matters

The clinical attrition rate for CNS therapeutics remains high, often due to the lack of predictive preclinical models that accurately reflect complex human neuropathology. Creative Biolabs' upgraded platform aims to address this challenge by providing a more holistic efficacy profile for pipeline candidates through integrated cognitive and neuromuscular assessments.

The details

The upgraded platform synchronizes testing modules to evaluate both cognitive decline and motor impairment, which often occur concomitantly in neurodegenerative diseases. For cognitive assessments, the company offers a suite of rodent behavioral tests such as the Morris Water Maze, Novel Object Recognition, and Y-Maze. For motor function, the platform includes automated Rotarod tests, grip strength measurements, and open-field locomotor tracking. The company also emphasizes minimizing environmental variability and aligning the appropriate behavioral paradigm to the chosen rodent model.

  • Creative Biolabs announced the platform expansion on March 21, 2026.

The players

Creative Biolabs

A company that provides in vivo pharmacology services and has expanded its rodent behavioral profiling platform to accelerate CNS drug discovery.

Director of In Vivo Pharmacology at Creative Biolabs

A spokesperson who commented on the importance of sensitive and reproducible behavioral assays for the predictive validity of CNS animal models.

Got photos? Submit your photos here. ›

What they’re saying

“The predictive validity of any CNS animal model relies heavily on the sensitivity and reproducibility of the behavioral assays applied.”

— Director of In Vivo Pharmacology

The takeaway

Creative Biolabs' upgraded rodent behavioral profiling platform aims to overcome the translational challenges in CNS drug discovery by providing a more comprehensive and standardized approach to evaluating both cognitive and motor functions in preclinical models, which is critical for developing effective therapeutics for neurodegenerative diseases.